Chemical: Drug
iloperidone

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


last updated 09/01/2016

1. FDA Label for iloperidone and CYP2D6

Actionable PGx
Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Schizophrenia
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • CYP2D6
    • dosage, metabolism/PK, Dosage & administration section, Drug interactions section, Clinical pharmacology section, Warnings and precautions section
    • source: U.S. Food and Drug Administration
  • CYP3A4
    • dosage, metabolism/PK, Dosage & administration section, Drug interactions section, Clinical pharmacology section, Warnings and precautions section
    • source: U.S. Food and Drug Administration

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for iloperidone

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1065852 NC_000022.10:g.42526694G=, NC_000022.10:g.42526694G>A, NC_000022.11:g.42130692G=, NC_000022.11:g.42130692G>A, NG_008376.3:g.4300C=, NG_008376.3:g.4300C>T, NM_000106.5:c.100C=, NM_000106.5:c.100C>T, NM_001025161.2:c.100C=, NM_001025161.2:c.100C>T, NP_000097.3:p.Pro34=, NP_000097.3:p.Pro34Ser, NP_001020332.2:p.Pro34=, NP_001020332.2:p.Pro34Ser, NT_187682.1:g.53033G=, NT_187682.1:g.53033G>A, NW_004504305.1:g.53019A=, NW_004504305.1:g.53019A>G, NW_009646208.1:g.16258A=, NW_009646208.1:g.16258A>G, XM_005278353.1:c.100T=, XM_005278353.1:c.100T>C, XM_005278354.1:c.-1454C>T, XM_005278354.1:c.-1454T>C, XM_005278354.3:c.-1454C>T, XM_005278354.3:c.-1454T>C, XM_011529966.1:c.100C=, XM_011529966.1:c.100C>T, XM_011529967.1:c.100C=, XM_011529967.1:c.100C>T, XM_011529968.1:c.100C=, XM_011529968.1:c.100C>T, XM_011529969.1:c.37+605C>T, XM_011529969.1:c.37+605T>C, XM_011529970.1:c.100C=, XM_011529970.1:c.100C>T, XM_011529971.1:c.37+605C>T, XM_011529971.1:c.37+605T>C, XM_011529972.1:c.100C=, XM_011529972.1:c.100C>T, XM_011547541.1:c.-1454C>T, XM_011547541.1:c.-1454T>C, XM_011547750.1:c.37+605C>T, XM_011547750.1:c.37+605T>C, XM_011547751.1:c.-1114C>T, XM_011547751.1:c.-1114T>C, XM_011547756.1:c.42+469A>G, XM_011547756.1:c.42+469G>A, XM_011548819.1:c.-1454C>T, XM_011548819.1:c.-1454T>C, XP_005278410.1:p.Ser34=, XP_005278410.1:p.Ser34Pro, XP_011528268.1:p.Pro34=, XP_011528268.1:p.Pro34Ser, XP_011528269.1:p.Pro34=, XP_011528269.1:p.Pro34Ser, XP_011528270.1:p.Pro34=, XP_011528270.1:p.Pro34Ser, XP_011528272.1:p.Pro34=, XP_011528272.1:p.Pro34Ser, XP_011528274.1:p.Pro34=, XP_011528274.1:p.Pro34Ser, XR_430455.2:n.328+4A>G, XR_430455.2:n.328+4G>A, XR_952536.1:n.-1751A>G, XR_952536.1:n.-1751G>A, XR_952537.1:n.-1751A>G, XR_952537.1:n.-1751G>A, XR_952538.1:n.-1751A>G, XR_952538.1:n.-1751G>A, XR_952539.1:n.-1462A>G, XR_952539.1:n.-1462G>A, XR_952745.1:n.1257C=, XR_952745.1:n.1257C>T, rs117813846, rs58862176
G > A
SNP
P34S
No VIP available No Clinical Annotations available VA
rs1800169 NC_000011.10:g.58624028G>A, NC_000011.9:g.58391501G>A, NG_008776.1:g.6356G>A, NM_000614.3:c.115-6G>A, NR_024091.1:n.1845-6G>A, rs17489651, rs386427934, rs57874465
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3813929 NC_000023.10:g.113818520C>T, NC_000023.11:g.114584047C>T, NG_012082.2:g.4963C>T, NM_000868.3:c.-759C>T, NM_001256760.2:c.-850C>T, NM_001256761.2:c.-759C>T, NW_004070891.1:g.252849C>T, rs17326402
C > T
SNP
No VIP available No Clinical Annotations available VA
rs3892097 NC_000022.10:g.42524947C=, NC_000022.10:g.42524947C>T, NC_000022.11:g.42128945C=, NC_000022.11:g.42128945C>T, NG_008376.3:g.6047G=, NG_008376.3:g.6047G>A, NM_000106.5:c.506-1A>G, NM_000106.5:c.506-1G>A, NM_001025161.2:c.353-1A>G, NM_001025161.2:c.353-1G>A, NT_187682.1:g.51286C=, NT_187682.1:g.51286C>T, NW_004504305.1:g.51272T=, NW_004504305.1:g.51272T>C, NW_009646208.1:g.14511C=, NW_009646208.1:g.14511C>T, XM_005278353.1:c.363-2A>G, XM_005278353.1:c.363-2G>A, XM_005278354.1:c.207-2A>G, XM_005278354.1:c.207-2G>A, XM_005278354.3:c.207-2A>G, XM_005278354.3:c.207-2G>A, XM_011529966.1:c.506-1A>G, XM_011529966.1:c.506-1G>A, XM_011529967.1:c.506-1A>G, XM_011529967.1:c.506-1G>A, XM_011529968.1:c.506-1A>G, XM_011529968.1:c.506-1G>A, XM_011529969.1:c.363-2A>G, XM_011529969.1:c.363-2G>A, XM_011529970.1:c.353-1A>G, XM_011529970.1:c.353-1G>A, XM_011529971.1:c.363-2A>G, XM_011529971.1:c.363-2G>A, XM_011529972.1:c.506-1A>G, XM_011529972.1:c.506-1G>A, XM_011547541.1:c.207-2A>G, XM_011547541.1:c.207-2G>A, XM_011547750.1:c.363-2A>G, XM_011547750.1:c.363-2G>A, XM_011547751.1:c.290-1A>G, XM_011547751.1:c.290-1G>A, XM_011547756.1:c.-1090C>T, XM_011547756.1:c.-1090T>C, XM_011548819.1:c.207-2A>G, XM_011548819.1:c.207-2G>A, XR_430455.2:n.-926C>T, XR_430455.2:n.-926T>C, XR_952745.1:n.1663-1A>G, XR_952745.1:n.1663-1G>A, rs1800716, rs28371711, rs60082401, rs606231227
C > T
SNP
No VIP available CA VA
rs4799915 NC_000018.10:g.37348676C>T, NC_000018.9:g.34928639C>T, NM_001025087.1:c.370-26795G>A, NM_001025088.1:c.370-26795G>A, NM_001025089.1:c.370-26795G>A, NM_020180.3:c.370-26795G>A, XM_005258300.1:c.370-26795G>A, XM_005258301.1:c.370-26795G>A, XM_005258302.1:c.370-26795G>A, XM_005258303.1:c.370-26795G>A, XM_005258304.1:c.370-26795G>A, XM_005258305.1:c.370-26795G>A, XM_005258306.1:c.370-26795G>A, XM_005258307.1:c.370-26795G>A, XM_005258308.1:c.370-26795G>A, XM_005258308.2:c.370-26795G>A, XM_005258309.1:c.370-26795G>A, XM_005258310.1:c.370-26795G>A, XM_005258311.1:c.370-26795G>A, XM_005258312.1:c.370-26795G>A, XM_005258313.1:c.370-26795G>A, XM_005258314.1:c.370-26795G>A, XM_011526079.1:c.370-26795G>A, XM_011526080.1:c.370-26795G>A, XM_011526081.1:c.370-26795G>A, XM_011526082.1:c.370-26795G>A, XM_011526083.1:c.370-26795G>A, XM_011526084.1:c.370-26795G>A, XM_011526085.1:c.370-26795G>A, XM_011526086.1:c.370-26795G>A, XM_011526087.1:c.370-26795G>A, XM_011526088.1:c.370-26795G>A, XM_011526089.1:c.370-26795G>A, XM_011526090.1:c.370-26795G>A, XM_011526091.1:c.370-26795G>A, XM_011526092.1:c.370-26795G>A, XM_011526093.1:c.370-26795G>A, XM_011526095.1:c.1-26795G>A, XM_011526096.1:c.1-26795G>A, XM_011526097.1:c.1-26795G>A, XR_243851.1:n.542-26795G>A, XR_935233.1:n.542-26795G>A, rs111173642, rs17653591, rs56976437, rs59639558
C > T
SNP
No VIP available CA VA
rs4933824 NC_000010.10:g.83819125T>G, NC_000010.11:g.82059369T>G, NG_013373.1:g.189056T>G, NM_001010848.3:c.823+183206T>G, NM_001165972.1:c.823+183206T>G, NM_001165973.1:c.61-107358T>G, XM_005269444.1:c.823+183206T>G, XM_005269444.3:c.823+183206T>G, XM_005269445.1:c.136-107358T>G, XM_005269446.1:c.136-107358T>G, XM_005269447.1:c.136-107358T>G, XM_005269448.1:c.61-107358T>G, XM_005269449.1:c.31+181349T>G, XM_005269450.1:c.31+181349T>G, XM_011539172.1:c.823+183206T>G, XM_011539173.1:c.823+183206T>G, XM_011539174.1:c.823+183206T>G, XM_011539175.1:c.823+183206T>G, XR_246059.1:n.823+183206T>G, rs60229764
T > G
SNP
No VIP available CA VA
rs7142881 NC_000014.8:g.32093548G>A, NC_000014.9:g.31624342G>A, NG_028349.1:g.67958G>A, NM_001201573.1:c.94+24963G>A, NM_025152.2:c.382+24963G>A, NR_120408.1:n.437+24963G>A, XM_005268099.1:c.382+24963G>A, XM_005268099.3:c.382+24963G>A, XM_005268100.1:c.-2+24963G>A, XM_011537181.1:c.107+24963G>A, XM_011537182.1:c.-74+24963G>A, XM_011537183.1:c.382+24963G>A, rs17481826, rs56464153, rs58372677
G > A
SNP
No VIP available CA VA
rs993648 NC_000002.11:g.182455994C>T, NC_000002.12:g.181591267C>T, NG_021178.1:g.70841G>A, NM_001030311.2:c.481+12570G>A, NM_001030312.2:c.481+12570G>A, NM_001030313.2:c.481+12570G>A, NM_001160277.1:c.481+12570G>A, NM_201548.4:c.481+12570G>A, NR_027689.1:n.582+12570G>A, NR_027690.1:n.582+12570G>A, rs386626019, rs56548045, rs59615415, rs59648679
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
Brand Mixture Names

PharmGKB Accession Id

PA161199368

Type(s):

Drug

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Chemical Properties

Isomeric SMILES

CC(=O)c1ccc(c(c1)OC)OCCCN2CCC(CC2)c3c4ccc(cc4on3)F

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Interactions

Interaction Description
ziprasidone - iloperidone Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. (source: Drug Bank )
zuclopenthixol - iloperidone Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )

Curated Information ?

Publications related to iloperidone: 6

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. Journal of clinical psychopharmacology. 2013. Potkin Steven G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics. 2010. Sicard Michelle N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Molecular psychiatry. 2009. Volpi S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. The Journal of clinical psychiatry. 2009. Volpi Simona, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. Pharmacogenomics. 2008. Lavedan Christian, et al. PubMed

LinkOuts

Clinical Trials

These are trials that mention iloperidone and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.